Life Extension Blood Test Super Sale

Anxiety References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Kessler RC, Ruscio AM, Shear K, Wittchen HU. Epidemiology of anxiety disorders. Curr Top BehavNeurosci. 2010;2:21-35.
  2. Bulloch AG, Currie S, Guyn L, Williams JV, Lavorato DH, Patten SB.Estimates of the treated prevalence of bipolar disorders by mental health services in the general population: comparison of results from administrative and health survey data. Chronic Dis Inj Can. 2011 Jun;31(3):129-34.
  3. Roberson-Nay R, Kendler KS. Panic disorder and its subtypes: a comprehensive analysis of panic symptom heterogeneity using epidemiological and treatment seeking samples.Psychol Med. 2011 Apr 18:1-11
  4. Kessler RC, Berglund PA, Demler O, Jin R, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry. 2005a Jun;62(6):593-602.
  5. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 2005b Jun;62(6):617-27.
  6. WeisbergRB. Overview of generalized anxiety disorder: epidemiology, presentation, and course. J Clin Psychiatry. 2009;70 Suppl 2:4-9.
  7. Wyrwich KW, Harnam N, Revicki DA, Locklear JC, Svedsater H, Endicott J. Assessment of quality of life enjoyment and satisfaction questionnaire-short form responder thresholds in generalized anxiety disorder and bipolar disorder studies. IntClinPsychopharmacol. 2011 May;26(3):121-9.
  8. Roy-Byrne PP, Wagner AW, SchraufnagelTJ. Understanding and treating panic disorder in the primary care setting. J Clin Psychiatry. 2005;66 Suppl 4:16-22.
  9. BienvenuOJ, Wuyek LA, Stein MB. Anxiety disorders diagnosis: some history and controversies. Curr Top BehavNeurosci. 2010;2:3-19.
  10. Merlo LJ, Storch EA. Obsessive-compulsive disorder: tools for recognizing its many expressions. J FamPract. 2006 Mar;55(3):217-22.
  11. Kessler RC, Ruscio AM, Shear K, Wittchen HU. Epidemiology of anxiety disorders. Curr Top BehavNeurosci. 2010;2:21-35.
  12. Machado-de-Sousa JP, Arrais KC, Alves NT, Chagas MH, de Meneses-Gaya C, Crippa JA, Hallak JE. Facial affect processing in social anxiety: tasks and stimuli. J Neurosci Methods. 2010 Oct 30;193(1):1-6.
  13. Coelho CM, Gonçalves DC, Purkis H, Pocinho M, Pachana NA, Byrne GJ. Specific phobias in older adults: characteristics and differential diagnosis. IntPsychogeriatr. 2010 Aug;22(5):702-11.
  14. Cantor C. Post-traumatic stress disorder: evolutionary perspectives. Aust N Z J Psychiatry. 2009 Nov;43(11):1038-48.
  15. Culpepper L. Generalized anxiety disorder and medical illness. J Clin Psychiatry. 2009;70 Suppl 2:20-4.
  16. Goodwin RD, Davidson KW, Keyes K. Mental disorders and cardiovascular disease among adults in the United States. J Psychiatr Res. 2009 Jan;43(3):239-46.
  17. Gureje O. Comorbidity of pain and anxiety disorders.Curr Psychiatry Rep. 2008 Aug;10(4):318-22.
  18. Ringbäck Weitoft G, Rosén M. Is perceived nervousness and anxiety a predictor of premature mortality and severe morbidity? A longitudinal follow up of the Swedish survey of living conditions. J Epidemiol Community Health. 2005 Sep;59(9):794-8.
  19. Levine J et al. Elevated serum homocysteine levels in male patients with PTSD. Depress Anxiety. 2008;25(11):E154-7.
  20. Coppen A et al. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol. 2005 Jan;19(1):59-65.
  21. De Souza MC, Walker AF, Robinson PA, Bolland K. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med. 2000 Mar;9(2):131-9.
  22. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70 Suppl 5:18-22.
  23. KrugersHJ et al. Chronic stress effects on hippocampal structure and synaptic function: relevance for depression and normalization by anti-glucocorticoid treatment. Front Synaptic Neurosci. 2010 Jul 12;2:24.
  24. van Riel E et al. Chronic unpredictable stress causes attenuation of serotonin responses in cornuammonis 1 pyramidal neurons. Neuroscience. 2003;120(3):649-58.
  25. KartenYJ et al. Long-term exposure to high corticosterone levels attenuates serotonin responses in rat hippocampal CA1 neurons. ProcNatlAcadSci U S A. 1999 Nov 9;96(23):13456-61.
  26. Anacker C et al. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol Psychiatry. 2011 Jul;16(7):738-50. doi: 10.1038/mp.2011.26. Epub 2011 Apr 12.
  27. Strohle A et al. Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry. 2003 Nov;36Suppl3:S207-14.
  28. Binder EB et al. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry. 2010 Jun;15(6):574-88. Epub 2009 Dec 15.
  29. Risbrough V. Behavioral correlates of anxiety. Curr Top BehavNeurosci. 2010;2:205-28.
  30. Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001848.
  31. Tolin DF. Is cognitive-behavioral therapy more effective than other therapies? A meta-analytic review. ClinPsychol Rev. 2010 Aug;30(6):710-20.
  32. Durant C, Christmas D, Nutt D. The pharmacology of anxiety. Curr Top BehavNeurosci. 2010;2:303-30.
  33. CloosJM, Ferreira V. Current use of benzodiazepines in anxiety disorders. CurrOpin Psychiatry. 2009 Jan;22(1):90-5.
  34. Bourin M, Lambert O. Pharmacotherapy of anxious disorders. Hum PsychopharmacolClin Exp. 2002;17:383–400.
  35. Feltner DE, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-bline, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011 Jul;26(4):213-20.
  36. Greist JH, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in preventing relapse in patients with generlized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol. 2011 Sep;26(5):243-51.
  37. Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. 2012 Apr;26(4):461-70.
  38. Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009;17(2):120-37.
  39. Parcells DA. Women's mental health nursing: depression, anxiety and stress during pregnancy.JPsychiatrMent Health Nurs. 2010 Nov;17(9):813-20.
  40. Bloch M, Azem F, Aharonov I, Ben Avi I, Yagil Y, Schreiber S, Amit A, Weizman A. GnRH-agonist induced depressive and anxiety symptoms during in vitro fertilization-embryo transfer cycles. FertilSteril. 2011
  41. Sundermann EE, Maki PM, Bishop JR.A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition. Menopause. 2010 Jul;17(4):874-86.
  42. Kikuchi H, Nakatani Y, Seki Y, Yu X, Sekiyama T, Sato-Suzuki I, Arita H. Decreased blood serotonin in the premenstrual phase enhances negative mood in healthy women.JPsychosomObstetGynaecol. 2010 Jun;31(2):83-9.
  43. Frye CA, Sumida K, Dudek BC, et al. Progesterone’s effects to reduce anxiety behavior of aged mice do not require actions via intracellular progestin receptors. Psycopharmacology (Berl). 2006 Jun;186(3):312-22.
  44. Saavedra m, Contreras CM, Azamar-Arizmendi G, et al. Differential progesterone effects on defensive burying and forced swimming tests depending upon a gradual decrease or an abrupt suppression schedules. Pharmacol Biochem Behav. 2006 Jan;83(1):130-5.
  45. Hachul H, Bittencourt LR, Andersen ML, et al. Effects of hormone therapy with estrogen and/or progesterone on sleep pattern in postmenopausal women. Int J Gynaecol Obstet. 2008 Dec;103(3):207-12.
  46. Ruiz AD et al. Effectiveness of compounded bioidentical hormone replacement therapy: an observational cohort study. BMC Womens Health. 2011 Jun 8;11:27.
  47. Khonicheva NM, Livanova LM, Tsykunov SG, et al. Blood testosterone in rats: correlation of the level of individual anxiety and its impairment after “death threat”. Neurosci Behav Physiol. 2008 Nov;38(9):985-9.
  48. Aikey JL, Nyby JG, Anmuth DM, et al. Testosterone rapidly reduces anxiety in male house mice (Mus musculus). Horm Behav. 2002 Dec;42(4):448-60.
  49. Strous RD, Maayan R, Kotler M, et al. Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients. Clin Neuropharmacol. 2005 Nov-Dec;28(6):265-9.
  50. Fernández-Guasti A, Martinez-Mota, L. Anxiolytic-like actions of testosterone in the burying behavior test: role of androgen and GABA-benzodiazepine receptors. Psychoneuroendocrinology. 2005 Sep;30(8):762-70.
  51. Jezova D, Hlavacova N. Endocrine factors in stress and psychiatric disorders: focus on anxiety and salivary steroids. Ann N Y Acad Sci. 2008 Dec;1148:495-503.
  52. Phillips AC, Carroll D, Gale, CR, et al. Cortisol, DHEA sulphate, their ratio, and all-cause and cause-specific mortality on the Vietnam Experience Study. Eur J Endocrinol. 2010 Aug;163(2):285-92.
  53. Binder G, Weber S, Ehrismann M, Zaiser N, Meisner C, Ranke MB, Maier L, Wudy SA, Hartmann MF, Heinrich U, Bettendorf M, Doerr HG, PfaeffleRW, Keller E; and the South German Working Group for Pediatric Endocrinology. Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial. J ClinEndocrinolMetab. 2009 Apr;94(4):1182-90.
  54. Abdali K, Khajehei M, Tabatabaee HR. Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study. Menopause. 2010 Mar;17(2):326-31.
  55. Al-Akoum M et al. Effects of Hypericumperforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. opause. 2009 Mar-Apr;16(2):307-14.
  56. Lipovac M, Chedraui P, Gruenhut C, Gocan A, Stammler M, Imhof M. Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts.Maturitas. 2010 Mar;65(3):258-61.
  57. Terzic MM et al. Influence of red clover-derived isoflavones on serum lipid profile in postmenopausal women. J ObstetGynaecol Res. 2009 Dec;35(6):1091-5.
  58. van Die MD, Bone KM, Burger HG, Reece JE, TeedeHJ. Effects of a combination of Hypericumperforatum and Vitexagnus-castus on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis. J Altern Complement Med. 2009 Sep;15(9):1045-8.
  59. Ishiwata N, Melby MK, Mizuno S, Watanabe S. New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause. 2009 Jan-Feb;16(1):141-8.
  60. Kalman DS, Feldman S, Feldman R et al: Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial. Nutr J, 2008; 7: 11
  61. Lewis BA, Martinson BC, Sherwood NE, Avery MD. A pilot study evaluating a telephone-based exercise intervention for pregnant and postpartum women. J Midwifery Womens Health. 2011 Mar-Apr;56(2):127-31.
  62. Xu Q, Anderson D, Courtney M. A longitudinal study of the relationship between lifestyle and mental health among midlife and older women in Australia: findings from the Healthy Aging of Women Study. Health Care Women Int. 2010 Dec;31(12):1082-96.
  63. Rogers PJ, Hohoff C, HeatherleySV, Mullings EL, MaxfieldPJ, Evershed RP, Deckert J, Nutt DJ.Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology. 2010 Aug;35(9):1973-83.
  64. CarekPJ, Laibstain SE, Carek SM. Exercise for the treatment of depression and anxiety. Int J Psychiatry Med. 2011;41(1):15-28.
  65. Streeter CC, Whitfield TH, Owen L, Rein T, Karri SK, Yakhkind A, Perlmutter R, Prescot A, Renshaw PF, Ciraulo DA, Jensen JE. Effects of yoga versus walking on mood, anxiety, and brain GABA levels: a randomized controlled MRS study. J Altern Complement Med. 2010 Nov;16(11):1145-52.
  66. Field T, Diego M, Hernandez-Reif M. Tai chi/yoga effects on anxiety, heartrate, EEG and math computations. Complement TherClinPract. 2010 Nov;16(4):235-8.
  67. Javnbakht M, HejaziKenari R, Ghasemi M. Effects of yoga on depression and anxiety of women. Complement TherClinPract. 2009 May;15(2):102-4.
  68. McRee LD, Noble S, Pasvogel A. Using massage and music therapy to improve postoperative outcomes. AORN J. 2003 Sep;78(3):433-42, 445-7.
  69. Deng G, Cassileth BR, Yeung KS. Complementary therapies for cancer-related symptoms. J Support Oncol. 2004 Sep-Oct;2(5):419-26; discussion 427-9.
  70. Pellino TA, Gordon DB, EngelkeZK, Busse KL, Collins MA, Silver CE, Norcross NJ. Use of nonpharmacologic interventions for pain and anxiety after total hip and total knee arthroplasty. OrthopNurs. 2005 May-Jun;24(3):182-90
  71. Lakhan SE, Vieira KF. Nutritional therapies for mental disorders. Nutr J. 2008;7:2.
  72. Sanchez-Villegas A, Delgado-Rodriguez M, Alonso A, et al. Association of the Mediterranean dietary pattern with the incidence of depression: the Seguimiento Universidad de Navarra/University of Navarra follow-up (SUN) cohort. Arch Gen Psychiatry. 2009 Oct;66(10):1090-8.
  73. Hood SD, Hince DA, Davies SJ, Argyropoulos S, Robinson H, Potokar J, Nutt DJ. Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. Psychopharmacology (Berl). 2010 Feb;208(2):223-32.
  74. Toker L, Amar S, Bersudsky Y, Benjamin J, Klein E. The biology of tryptophan depletion and mood disorders. Isr J Psychiatry Relat Sci. 2010;47(1):46-55.
  75. Beacher FD, Gray MA, Minati L, et al. Acute tryptophan depletion attenuates conscious appraisal of social emotional signals in healthy female volunteers. Psychopharmacology (Berl). 2011 Feb;213(2-3):603-13.
  76. Roiser JP, Levy J, Fromm SJ, Wang H, Hasler G, Sahakian BJ, Drevets WC. The effect of acute tryptophan depletion on the neural correlates of emotional processing in healthy volunteers. Neuropsychopharmacology. 2008 Jul;33(8):1992-2006.
  77. Feurte S, Gerozissis K et al. Plasma Trp/LNAA ratio increases during chronic ingestion of an alpha-lactalbumin diet in rats. NutrNeurosci. 2001;4(5):413–8.
  78. Lakhan SE, Vieira KF. Nutritional therapies for mental disorders. Nutr J. 2008 Jan;7:2.
  79. Ghosh S, Smriga M, Vuvor F, Suri D, Mohammed H, Armah SM, Scrimshaw NS. Effect of lysine supplementation on health and morbidity in subjects belonging to poor peri-urban households in Accra, Ghana. Am J ClinNutr. 2010 Oct;92(4):928-39
  80. Smriga M, Ghosh S, Mouneimne Y, Pellett PL, Scrimshaw NS. Lysine fortification reduces anxiety and lessens stress in family members in economically weak communities in Northwest Syria. ProcNatlAcadSci U S A. 2004 Jun 1;101(22):8285-8.
  81. Smriga M, Torii K. L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats. ProcNatlAcadSci U S A. 2003 Dec 23;100(26):15370-5. Epub 2003 Dec 15.
  82. Jezova D, Makatsori A, Smriga M, Morinaga Y, Duncko R. Subchronic treatment with amino acid mixture of L-lysine and L-arginine modifies neuroendocrine activation during psychosocial stress in subjects with high trait anxiety. NutrNeurosci. 2005 Jun;8(3):155-60.
  83. Lakhan SE, Vieira KF. Nutritional therapies for mental disorders. Nutr J. 2008 Jan 21;7:2.
  84. Smriga M, Ando T, Akutsu M, Furukawa Y, Miwa K, Morinaga Y. Oral treatment with L-lysine and L-arginine reduces anxiety and basal cortisol levels in healthy humans. Biomed Res. 2007 Apr;28(2):85-90.
  85. Weeks BS. Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action: Relarian. Med SciMonit. 2009 Nov;15(11):RA256-62.
  86. Heese T, Jenkinson J, Love C, Milam R, Perkins L, Adams C, McCall S, CeremugaTE. Anxiolytic effects of L-theanine--a component of green tea--when combined with midazolam, in the male Sprague-Dawley rat. AANA J. 2009 Dec;77(6):445-9.
  87. Rogers PJ, Smith JE, HeatherleySV, Pleydell-Pearce CW. Time for tea: mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. Psychopharmacology (Berl). 2008 Jan;195(4):569-77.
  88. Kakuda T. Neuroprotective effects of theanine and its preventive effects on cognitive dysfunction. Pharmacol Res. 2011 Aug;64(2):162-8.
  89. Cho HS, Kim S, Lee SY, Park JA, Kim SJ, Chun HS. Protective effect of the green tea component, L-theanine on environmental toxins-induced neuronal cell death. Neurotoxicology. 2008 Jul;29(4):656-62.
  90. Ritsner MS, Miodownik C, Ratner Y, et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry. 2011 Jan;72(1):34-42.
  91. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002 Nov;76(5):1158S-61S.
  92. Shippy RA et al. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. BMC Psychiatry. 2004 Nov 11;4:38.
  93. Sartori SB, Whittle N, Hetzenauer A, et al. Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment. Neuropharmacology. 2012;62(1):304-12.
  94. Carroll D, Ring C, Suter M, Willemsen G. The effects of an oral multivitamin combination with calcium, magnesium, and zinc on psychological well-being in healthy young male volunteers: a double-blind placebo-controlled trial. Psychopharmacology (Berl). 2000 Jun;150(2):220-5.
  95. De Souza MC, Walker AF, Robinson PA, et al. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med. 2000 Mar;9(2):131-9.
  96. Hanus M, Lafon J, Mathieu M. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegusoxyacantha and Eschscholtziacalifornica) and magnesium in mild-to-moderate anxiety disorders. Curr Med Res Opin. 2004 Jan;20(1):63-71.
  97. Jacka FN, Overland S, Stewart R, et al. Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study. Aust N Z J Psychiatry. 2009 Jan;43(1):45-52.
  98. Slutsky I et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010 Jan 28;65(2):165-77.
  99. Benton D, Cook R. Selenium supplementation improves mood in a double-blind crossover trial. Psychopharmacology (Berl). 1990;102(4):549-50.
  100. Benton D, Cook R. The impact of selenium supplementation on mood. Biol Psychiatry. 1991 Jun 1;29(11):1092-8.
  101. Mokhber N, Namjoo M, Tara F, Boskabadi H, Rayman MP, Ghayour-Mobarhan M, Sahebkar A, MajdiMR, Tavallaie S, Azimi-Nezhad M, Shakeri MT, Nematy M, Oladi M, Mohammadi M, Ferns G. Effect of supplementation with selenium on postpartum depression: a randomized double-blind placebo-controlled trial. J Matern Fetal Neonatal Med. 2011 Jan;24(1):104-8.
  102. Gosney MA, Hammond MF, Shenkin A, Allsup S. Effect of micronutrient supplementation on mood in nursing home residents. Gerontology. 2008;54(5):292-9.
  103. Bargellini A, Piccinini L, De Palma M, Giacobazzi P, Scaltriti S, Mariano M, Roncaglia R, Borella P. Trace elements, anxiety and immune parameters in patients affected by cancer. J Trace Elem Med Biol. 2003;17 Suppl 1:3-9.
  104. Shor-Posner G, Lecusay R, MiguezMJ, Moreno-Black G, Zhang G, Rodriguez N, Burbano X, Baum M, Wilkie F. Psychological burden in the era of HAART: impact of selenium therapy. Int J Psychiatry Med. 2003;33(1):55-69.
  105. Duntas LH. Selenium and the thyroid: a close-knit connection. J Clin Endocrinol Metab. 2010;95(12):5180-8.
  106. Perica MM, Delas I. Essential Fatty acids and psychiatric disorders. NutrClinPract. 2011 Aug;26(4):409-25.
  107. Ross BM Omega-3 polyunsaturated fatty acids and anxiety disorders. Prostaglandins LeukotEssent Fatty Acids. 2009 Nov-Dec;81(5-6):309-12.
  108. Appleton KM, Rogers PJ, Ness AR. Is there a role for n-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutr Res Rev. 2008 Jun;21(1):13-41.
  109. Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation lowers inflammation and anxiety in medical students: A randomized controlled trial. Brain Behav Immun. 2011
  110. Buydens-Branchey L, Branchey M, Hibbeln JR. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. ProgNeuropsychopharmacolBiol Psychiatry. 2008 Feb 15;32(2):568-75.
  111. Yehuda S, Rabinovitz S, Mostofsky DI. Mixture of essential fatty acids lowers test anxiety. NutrNeurosci. 2005 Aug;8(4):265-7.
  112. Head KA, Kelly GS. Nutrients and botanicals for treatment of stress: adrenal fatigue, neurotransmitter imbalance, anxiety, and restless sleep. Altern Med Rev. 2009 Jun;14(2):114-40.
  113. Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed G. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl) 2009;205:399–407.
  114. Chiappedi M, Bejor M. Herbals and natural dietary supplements in psychiatric practice. Recent Pat CNS Drug Discov. 2010 Jun;5(2):164-71.
  115. Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiolarosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine. 2010 Jun;17(7):481-93.
  116. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. EurNeuropsychopharmacol. 2011 May 20.
  117. Saeed SA, Bloch RM, Antonacci DJ. Herbal and dietary supplements for treatment of anxiety disorders. Am Fam Physician. 2007 Aug 15;76(4):549-56.
  118. Linde K. St. John's wort - an overview.ForschKomplementmed. 2009 Jun;16(3):146-55.
  119. van der Watt G, Laugharne J, Janca A. Complementary and alternative medicine in the treatment of anxiety and depression. CurrOpin Psychiatry. 2008 Jan;21(1):37-42.
  120. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD000448.
  121. Tadros MG, Mohamed MR, Youssef AM, Sabry GM, Sabry NA, Khalifa AE. Involvement of serotoninergic 5-HT1A/2A, alpha-adrenergic and dopaminergic D1 receptors in St. John's wort-induced prepulse inhibition deficit: a possible role of hyperforin. Behav Brain Res. 2009 May 16;199(2):334-9.
  122. Ara I, Bano S. St. John's Wort modulates brain regional serotonin metabolism in swim stressed rats. Pak J Pharm Sci. 2009 Jan;22(1):94-101.
  123. Canning S, Waterman M, Orsi N, Ayres J, Simpson N, Dye L. The efficacy of Hypericumperforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010 Mar 1;24(3):207-25.
  124. van Die MD, Bone KM, Burger HG, Reece JE, TeedeHJ. Effects of a combination of Hypericumperforatum and Vitexagnus-castus on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis. J Altern Complement Med. 2009 Sep;15(9):1045-8.
  125. MannelM.Drug interactions with St John's wort : mechanisms and clinical implications. Drug Saf. 2004;27(11):773-97.
  126. Walesiuk A, BraszkoJJ. Preventive action of Ginkgo biloba in stress- and corticosterone-induced impairment of spatial memory in rats. Phytomedicine. 2009 Jan;16(1):40-6.
  127. Kuribara H, Weintraub ST, Yoshihama T, Maruyama Y. An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice. J Nat Prod. 2003 Oct;66(10):1333-7.
  128. Woelk H, ArnoldtKH, Kieser M, HoerrR.Ginkgobiloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2007 Sep;41(6):472-80.
  129. Faustino TT, de Almeida RB, Andreatini R. Medicinal plants for the treatment of generalized anxiety disorder: a review of controlled clinical studies. Rev Bras Psiquiatr. 2010 Dec;32(4):429-36.
  130. Ortiz JG, Nieves-Natal J, Chavez P: Effects of Valerianaofficinalisextractson [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res, 1999; 24(11): 1373–78
  131. Yuan CS, Mehendale S, Xiao Y et al: The gamma-aminobutyricacidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. AnesthAnalg, 2004; 98(2): 353–58.
  132. Khom S, Baburin I, Timin E et al: Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specifi city. Neuropharmacology, 2007; 53(1): 178–87
  133. Trauner G, Khom S, Baburin I et al: Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Med, 2008; 74(1): 19–24
  134. Benke D, Barberis A, Kopp S et al: GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology. 2009; 56(1): 174–81
  135. Hadjikhani R: Anxiolytic-like Effects of Dichloromethane Extracts of Valerian (DEV) in Adult Male Wistar Rats. World Academy of Science, Engineering and Technology, 2009; (55): 532–36
  136. Hattesohl M, Feistel B, Sievers H et al: Extracts of ValerianaofficinalisL.s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine, 2008; 15(1–2): 2–15
  137. Awad R, Levac D, Cybulska P et al: Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can J PhysiolPharmacol, 2007; 85(9): 933–42
  138. Andreatini R, Sartori VA, Seabra ML, Leite JR: sEffect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo- controlled pilot study. Phytother Res, 2002; 16(7): 650–54
  139. Muller SF, Klement S: A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine, 2006; 13(6): 383–87
  140. Bhattacharyya D, Jana U, DebnathPK, Sur TK: Initial exploratory observational pharmacology of Valerianawallichii on stress management: a clinical report. Nepal Med Coll J, 2007; 9(1): 36–39
  141. Kennedy DO, Little W, Haskell CF, Scholey AB: Anxiolytic effects of a combination of Melissa officinalis and Valerianaofficinalis during laboratory induced stress. Phytother Res, 2006; 20(2): 96–102
  142. Yoo DY, Choi JH, Kim W, et al. Effects of Melissa officinalis L. (lemon balm) extract on neurogenesis associated with serum corticosterone and GABA in the mouse dentate gyrus. Neurochem Res. 2011 Feb;36(2):250-7.
  143. Ibarra A, Feuillere N, Roller M, et al. Effects of chronic administration of Melissa officinalis L. extract on anxiety-like reactivity and on circadian and exploratory activities in mice. Phytomedicine. 2010 May;17(6):397-403.
  144. Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med. 2008;14(2):175-80.
  145. Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med. 2008 Mar;14(2):175-80.
  146. Mattioli L, Perfumi M. Evaluation of Rhodiola rosea L. extract on affective and physical signs of nicotine withdrawal in mice. J Psychopharmacol. 2011 Mar;25(3):402-10.
  147. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withaniasomnifera (ashwagandha): a review. Altern Med Rev. 2000 Aug;5(4):334-46.
  148. Mohan L, Rao US, GopalakrishnaHN, Nair V. Evaluation of the Anxiolytic Activity of NR-ANX-C (a Polyherbal Formulation) in Ethanol Withdrawal-Induced Anxiety Behavior in Rats. Evid Based Complement Alternat Med. 2011;2011.
  149. Kulkarni SK, Singh K, BishnoiM.Comparativebehavioural profile of newer antianxiety drugs on different mazes. Indian J Exp Biol. 2008 Sep;46(9):633-8.
  150. Ramanathan M, Balaji B, Justin A. Behavioural and neurochemical evaluation of Perment an herbal formulation in chronic unpredictable mild stress induced depressive model. Indian J Exp Biol. 2011 Apr;49(4):269-75.
  151. Andrade C. Ashwagandha for anxiety disorders.World J Biol Psychiatry. 2009;10(4 Pt 2):686-7.
  152. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Anxiolytic-antidepressant activity of Withaniasomniferaglycowithanolides: an experimental study. Phytomedicine. 2000 Dec;7(6):463-9.
  153. Cooley K, Szczurko O, Perri D, Mills EJ, Bernhardt B, Zhou Q, Seely D. Naturopathic care for anxiety: a randomized controlled trial ISRCTN78958974. PLoS One. 2009 Aug 31;4(8):e6628.
  154. Nemeroff CB: The role of GABA in thepathophysiology and treatment of anxiety disorders. Psychopharmacol Bull, 2003; 37: 133–46
  155. Kendell SF, Krystal JH, Sanacora G: GABAandglutamate systems as therapeutic targets in depressionand mood disorders. Expert OpinTher Targets, 2005; 9: 153–68
  156. Kugaya A, Sanacora G: Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr, 2005; 10: 808–19
  157. Bazil CW, Battista J, Basner RC: Gabapentinimproves sleep in the presence of alcohol. J ClinSleepMed, 2005; 1: 284–87
  158. Abdou AM, Higashiguchi S, Horie K et al: Relaxation and immunity enhancement effects of gamma aminobutyric acid (GABA) administration in humans. Biofactors, 2006; 26(3): 201–8
  159. Thorne Research, Inc: Gamma-Aminobutyric Acid (GABA). Alternative Medicine Review, 2007; 12(3)
  160. Berk M, Jeavons S, Dean OM, et al. Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting. CNS Spectr. 2009 Jul;14(7):357-60.
  161. Magalhães PV, Dean OM, Bush AI, et al. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disord. 2011 Mar;129(1-3):317-20.
  162. Kalueff Av, Lou YR, Laaksi I, et al. Increased anxiety in mice lacking vitamin D receptor gene. Neuroreport. 2004 Jun;15(8):1271-4.
  163. Parker G, Brotchie H. ‘D’ for depression: any role for vitamin D? ‘Food for Thought’ II. Acta Psychiatr Scand. 2011 Oct;124(4):243-9.